Navigation Links
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Date:5/28/2008

rcialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulatio
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Announces Upcoming Conference Participation
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
6. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... BioTime, Inc. (OTCBB:BTIM) announced today that Robert N. ... of Directors. Dr. Butler is the founder, Chief ... Center-USA, a non-profit international research, policy, and education ... live longer and better, and advise society on ...
... service revenue grows approximately 33% ... - Operating margin of 9.9% ... ... 6 PAREXEL International,Corporation (Nasdaq: PRXL ) today announced its financial results for the,fourth quarter and ...
... BioSciences announced,today the successful acquisition of funding ... the development of a long lasting, safe, ... a consortium of,microbicide researchers from four major ... from the portfolio of microbicides,being developed by ...
Cached Biology Technology: Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 2 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 3 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 2ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission 3
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... in Spanish . Xabier Basogain Olabe ... Engineering in Bilbao, is leading this project, known as Bonis. ... visual monitoring of epidemiology in isolated areas of Paraguay and ... practical trials will begin shortly and it is hoped to ...
... Two genes have been associated with autistic spectrum ... Researchers writing in BioMed Central,s newly launched journal ... for two brain proteins, LRRN3 and LRRTM3, were significantly ... the Wellcome Trust Centre for Human Genetics, University of ...
... twist. No small feat. Now the flexible and stretchable ... heart with better resolution and speed than that of ... the University of Illinois at Urbana-Champaign and the University ... silicon electronics device used for a medical application. The ...
Cached Biology News:University of the Basque Country develops system for identifying illnesses in Paraguay 2University of the Basque Country develops system for identifying illnesses in Paraguay 3Hugging the heart electronically 2Hugging the heart electronically 3
...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
Biology Products: